What is new in BNF 52?|
by BNF - 14169 reads, based on 7 votes
Long-acting beta2 agonists
The safety of long-acting beta2 agonists has come under close scrutiny, particularly following the recent publication of a meta-analysis (Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904–912). BNF 52 includes advice developed with the Commission on Human Medicines on the safe use of formoterol and salmeterol (section 18.104.22.168). It is important that use of a long-acting beta2 agonist accords with the guidance on stepwise management of chronic asthma (section 3.1) and that the drug is withdrawn in the absence of benefit....